Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus

• Published in: Antiviral Chemistry and Chemotherapy 2018-01, Vol.26, p.2040206618770518-2040206618770518
• Main Authors: Boukhvalova, MS, Yim, KC, Blanco, JCG
• Format: Article
• Language: English
• Subjects: Animal models; Antiviral agents; Antiviral drugs; Bronchopneumonia; Clinical trials; Cotton; Geriatrics; Health risks; Immunization; Immunoprophylaxis; Immunosuppression; Infants; Infections; Interferon; Monoclonal antibodies; Respiratory syncytial virus; Review; Risk groups; Vaccines
• ISSN: 2040-2066; 0956-3202; 2040-2066
• DOI: 10.1177/2040206618770518

Respiratory syncytial virus is the leading cause of pneumonia and bronchiolitis in infants and is a serious health risk for elderly and immunocompromised individuals. No vaccine has yet been approved to prevent respiratory syncytial virus infection and the only available treatment is immunoprophylaxis of severe respiratory syncytial virus disease in high-risk infants with Palivizumab (Synagis®). The development of respiratory syncytial virus vaccine has been hampered by the phenomenon of enhanced respiratory syncytial virus disease observed during trials of a formalin-inactivated respiratory syncytial virus in 1960s. A search for effective respiratory syncytial virus therapeutics has been complicated by the fact that some of the most advanced respiratory syncytial virus antivirals, while highly effective in a prophylactic setting, had not demonstrated clinical efficacy when given after infection. A number of respiratory syncytial virus vaccines and antivirals are currently under development, including several vaccines proposed for maternal immunization. The cotton rat Sigmodon hispidus is an animal model of respiratory syncytial virus infection with demonstrated translational value. Special cohort scenarios, such as infection under conditions of immunosuppression and maternal immunization have been modeled in the cotton rat and are summarized here. In this review, we focus on the recent use of the cotton rat model for testing respiratory syncytial virus vaccine and therapeutic candidates in preclinical setting, including the use of special cohort models. An overview of published studies spanning the period of the last three years is provided. The emphasis, where possible, is made on candidates in the latest stages of preclinical development or currently in clinical trials.